Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Combination Antidepressant Therapy in Clinical Practice

Prevalence and Clinical Scenarios

  • The American Academy of Child and Adolescent Psychiatry suggests that combination antidepressant therapy is relatively common in treatment-resistant depression, with scenarios including transition periods when switching from one antidepressant to another, treatment-resistant depression when monotherapy has failed, treating multiple concurrent disorders, and augmentation to address specific symptom profiles 1, 2, 3, 4, 5
  • Combination antidepressant therapy may be used for treating multiple concurrent disorders, such as depression with anxiety, under the guidance of a qualified healthcare professional 1, 3

Evidence Base for Combination Therapy

  • Current guidelines from the American Academy of Child and Adolescent Psychiatry indicate limited empirical support for combining medications from the same class, such as two SSRIs or two SNRIs 1, 2
  • For treatment-resistant OCD, evidence supports augmentation strategies, including adding an antipsychotic to an SSRI or combining an SSRI with clomipramine, a tricyclic antidepressant, as recommended by the American Academy of Child and Adolescent Psychiatry 4, 5
  • The American Academy of Child and Adolescent Psychiatry recommends that combinations such as SSRI plus antipsychotic may be considered for certain conditions, with careful monitoring for adverse effects 4, 5

Safety Considerations and Risks

  • The American Academy of Child and Adolescent Psychiatry warns that the most serious risk of combining serotonergic antidepressants is serotonin syndrome, which can be life-threatening, and particular caution is required when combining any antidepressant with MAOIs or two or more serotonergic drugs 6, 7, 8
  • The American Academy of Child and Adolescent Psychiatry advises that drug-drug interactions may occur through pharmacokinetic or pharmacodynamic interactions, and close monitoring is necessary when combining antidepressants with other medications that affect serotonin 7, 8

Clinical Decision-Making Algorithm

  • The American Academy of Child and Adolescent Psychiatry recommends starting with antidepressant monotherapy, allowing an adequate trial, and monitoring for response and side effects, with consideration of switching to a different antidepressant or augmentation with psychotherapy if necessary 4, 9
  • For treatment-resistant cases, the American Academy of Child and Adolescent Psychiatry suggests considering evidence-based augmentation strategies with medications having different mechanisms, such as SSRI plus antipsychotic, and avoiding combinations of two medications from the same class 1, 2, 4, 5
  • When implementing combination therapy, the American Academy of Child and Adolescent Psychiatry recommends developing a clear treatment and monitoring plan, educating the patient about potential risks and benefits, starting the second agent at a low dose, and monitoring closely for adverse effects 1, 3, 6, 8

Common Pitfalls to Avoid

  • The American Academy of Child and Adolescent Psychiatry cautions against combining antidepressants without a clear rationale or evidence base, using combinations based solely on theoretical neurotransmitter effects, failing to monitor for drug-drug interactions, and not having a plan for discontinuation if the combination proves ineffective or causes adverse effects 1, 2, 3, 8

REFERENCES